Effect of Atorvastatin as a Renal Protection in Patients With Systemic Inflammatory Response Syndrome Using Renal Arterial Resistive Index

Phase 1UnknownNCT05946122

Minia University106 enrolled

Overview

Offering renal protection in systemic inflammatory response syndrome by atorvastatin

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

106

Conditions

Renal Protection

Interventions

Atorvastatin 40 Mg Oral TabletDRUG

oral atorvastatin for renal protection

placebo drugDRUG

tablet resembles atorvastatin

Eligibility

Sex: ALLMin age: 25 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients ( male and female) with systemic inflammatory response ( total leucocytic count \>12,000 mm3'. temperature \>38 C, Heart rate \>90 b/min and respiratory rate\>20 cycle). Exclusion Criteria: * Hemodynamic instability * Pre-admission chronic kidney disease. * Intra-vascular coagulopathy * Patients with myopathy.

Locations (1)

Mina Maher Raouf

Minya, Minia University, Egypt

RECRUITING

Outcomes

Primary Outcomes

Acute kidney injury

incidence or acute kidney injury

Time frame: one week

Secondary Outcomes

renal resistive vascular index

renal resistive index

Time frame: one week

APACHE score ( acute physiology and chronic health evaluation)

acute physiology and chronic health evaluation, values below 40 are considered normal while values between 41 and 71 are considered abnormal .

Time frame: one week

length of ICU stay

days of ICU admission

Time frame: two weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.